My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

91.63 +0.95 (+1.05%)

Streaming Delayed Price Updated: 2:16 PM EST, Feb 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Kymera Therapeutics Inc (NASDAQ:KYMR) Stock Falls 6.6% After Q4 2025 Earnings Miss and Extended Clinical Timelines ↗

Today 8:22 EST

Via Chartmill

Topics Earnings

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

What to Expect from Kymera Therapeutics's Earnings ↗

August 08, 2025

Via Benzinga

Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet ↗

February 23, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.

Via The Motley Fool

Topics Regulatory Compliance

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks ↗

January 01, 2026

Via MarketBeat

Streaming Wars Go Hostile Just as Wall Street Braces for the Fed ↗

December 09, 2025

Stocks slipped from record levels on Monday as investors shifted into “wait-and-see” mode ahead of Wednesday’s Fed decision. At the same time, Hollywood turned into a live-fire M&A battlefield, with...

Via Chartmill

Topics Economy

What's going on in today's session ↗

December 08, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

December 08, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

December 08, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Why Is KYMR Stock Up 30% Pre-Market Today? ↗

December 08, 2025

Kymera Therapeutics stated that its BroADen clinical trial of KT-621 showed that it achieved median reductions of STAT6 degradation of 94% and 98% in skin and blood in 100mg and 200mg dose groups.

Via Stocktwits

Topics Economy

These stocks are moving in today's after hours session ↗

December 05, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Kymera (KYMR) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Analysts Have This To Say About Kymera Therapeutics ↗

November 05, 2025

Via Benzinga

Kymera Therapeutics Inc (NASDAQ:KYMR) Q3 2025 Earnings: Clinical Progress Overshadows Financial Miss ↗

November 04, 2025

Kymera Therapeutics stock rises on positive clinical updates for its atopic dermatitis drug, KT-621, despite missing Q3 2025 revenue and EPS estimates.

Via Chartmill

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts ↗

October 17, 2025

Via Benzinga

Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views ↗

September 16, 2025

Via Benzinga

This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

September 16, 2025

Via Benzinga

Kymera Therapeutics Inc (NASDAQ:KYMR) Reports Q2 2025 Earnings Miss, Stock Dips Pre-Market ↗

August 11, 2025

Kymera Therapeutics Q2 2025 earnings miss estimates with $11.48M revenue (-55% YoY) and $0.95 EPS loss. Stock drops 2.7% pre-market despite clinical progress in STAT6 candidate.

Via Chartmill

Topics Earnings

Kymera Revenue Drops 55 Percent in Q2 ↗

August 11, 2025

Via The Motley Fool

Topics Intellectual Property

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' ↗

July 09, 2025

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.

Via Benzinga

Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock ↗

June 26, 2025

Via Benzinga

Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday ↗

June 26, 2025

Via Benzinga

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit ↗

June 25, 2025

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.

Via Stocktwits

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies ↗

June 25, 2025

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Via Benzinga

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

June 25, 2025

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.